Olympus shares the public concern regarding reports connecting duodenoscopes to infections by drug resistant bacteria, specifically CRE or carbapenem-resistant Enterobacteriaceae. We express our sympathy to those who have experienced these infections.

Olympus remains committed to developing solutions for healthcare professionals that help improve clinical outcomes and enhance quality of life for their patients. We continuously strive to improve our medical devices for safe and effective use.

The current issue with respect to reports connecting duodenoscopes to infections by CRE is receiving the highest level of attention within the Company. We are investigating the situation with respect to our TJF-Q180V duodenoscope in the United States and working with the United States Food and Drug Administration (FDA), other competent authorities, relevant medical societies and our customers to enhance safeguards with respect to cleaning and reprocessing this model on a global basis.